Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 2011. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding changes in interests in the company's ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a specific director transaction and does not contain consolidated financial statements or performance metrics.
Material Changes
No material changes to the company's financial position or operations are reported in this document. The filing details a specific equity transaction by a director rather than corporate-level financial changes.
Management Commentary and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly reports a transaction executed in accordance with Disclosure Rule 3.1.4R(1)(a).
Important Facts for Investors
- Director Transaction: Dr. M M Slaoui exercised options on 45,000 ordinary shares on November 4, 2011.
- Exercise Price: The options were granted on December 3, 2002, with an exercise price of £11.79 per share.
- Share Sale: Immediately following the exercise, 45,000 ordinary shares were sold on November 4, 2011, at a price of £13.77 per share.
- Notification Date: The company and the director were advised of this transaction on November 4, 2011.